496Prior M184V/I and multiple prior virological failures have no impact on the efficacy of switching HIV+ adults to DTG/3TC through 96Wks in SOLAR-3D



G. Blick1, E. Cerreta1, G. Mancini1, A. Cosenza1, L. Fang2 1Health Care Advocates International, Stratford, United States, 2Pharstat Inc., Raleigh, United States


BACKGROUND: DTG/3TC is approved for virologically suppressed HIV+ adults switching from stable ART with no prior DTG or 3TC resistance or prior virologic/treatment failure. SOLAR-3D prospectively evaluated the ability of DTG/3TC to maintain virologic suppression in adults switched in the setting of prior and current M184V/I and multiple virologic failures.
METHODS: SOLAR-3D is a prospective, open-label, comparative 96-week study of HIV-1+ adults virologically suppressed for =6mos, with =3 prior ART and prior virologic failures, enrolled from May 2019-April 2020 and stratified by history of prior M184V/I. There were no exclusions for prior INSTI use, any CD4, prior M184V/I, or 3TC-associated mutations detected at BL by proviral DNA NGS.
Primary and Secondary Efficacy Endpoints: participants with PCR=50 at Wk48 and 96, resp. by FDA snapshot (ITT-E and PP). Additional Secondary Endpoints: PCR< 50 at Wk48 and 96 (ITT-E, PP), incidence of AEs and discontinuation due to CVF (PCR=50 followed by PCR >200).
RESULTS: 100 adults switched to DTG/3TC, n=50 with historical/prior M184V/I (n=15 with current M184V/I by proviral DNA NGS) and n=50 without prior M184V/I. Those with prior M184V/I had more prior virologic failures (n[IQR]: 9[7-13]v4[3-5], p<0.001) and longer median duration HIV (28.4v15.5yrs, p<0.001), were older, and had lower nadir CD4, longer ART duration, and longer duration PCR<50c/mL. Median time on DTG/3TC was137wks for both groups.
At Wks 48 and 96, no difference in efficacy was observed in those with prior M184V/I compared to those without prior M184V/1:

CONCLUSIONS: Through 96wks, SOLAR-3D, the largest prospective trial evaluating DTG/3TC switch in individuals with prior 3TC-associated mutations, confirms prior history/current presence of M184V/I doesn't impact the efficacy of switching virologically suppressed HIV+ adults with multiple prior virologic failures.